A deep dive into Pantech Group Holdings Berhad's valuation using a Discounted Cash Flow model suggests the stock may be trading close to its intrinsic value, offering investors a potential entry point in the industrial supplies sector.
The Singapore-listed food company has turned profitable after years of losses, with a 12% return on capital employed and a significant expansion in its capital base—key indicators watched by investors seeking compounding growth stocks.
Nomura Holdings reported robust Q3 results, with its four main divisions hitting an 18.5-year profit high and ROE consistently exceeding targets. However, losses in its digital asset unit tempered overall gains, prompting the firm to announce a significant share repurchase program.
Parker-Hannifin posts record-breaking Q2 fiscal 2026 results, fueled by robust organic growth and margin expansion, particularly in aerospace. The industrial giant raises full-year guidance and details strategic progress on its planned acquisition of Filtration Group Corporation.
Piper Sandler raises its price target on Kura Sushi USA (KRUS) following an investor meeting, citing potential from recent changes to its digital loyalty platform. The company also appointed a new marketing-focused director as it eyes U.S. expansion.
TOPEKA — Kansas's popular Learning Quest 529 savings plans are set for a significant upgrade next month, promising families new investment options, enhanced planning tools, and reduced management fees under a new administrator, State Treasurer Steven Johnson announced.
Israel and Egypt have initiated a tightly controlled pilot reopening of the Rafah border crossing, a move tied to the broader U.S.-backed peace framework. The initial phase permits a small number of pre-vetted individuals to cross daily under heavy security coordination.
As Pfizer prepares to report its fourth-quarter results, investors are weighing the company's strategic pivot beyond its COVID-19 portfolio against a backdrop of expected revenue declines. The report may set the tone for the broader pharmaceutical sector.
A discounted cash flow analysis suggests shares of the Malaysian poultry and seafood firm may be overvalued at current levels, raising questions for investors.
As Smurfit Westrock navigates the complex post-merger landscape, its share price tells a conflicted story. While recent gains hint at optimism, a deeper look reveals a stock trading at a significant discount to some intrinsic value models, even as its P/E ratio suggests a premium. The market appears to be weighing integration execution risks against long-term synergy potential.
New long-term results from the pivotal EMBARK trial indicate ELEVIDYS, Sarepta's gene therapy, continues to alter the disease trajectory for boys with Duchenne muscular dystrophy, with no new safety concerns emerging over three years.
The stablecoin issuer finished 2025 with over $10 billion in net profit, backed by a $17.4 billion gold reserve and a U.S. Treasury portfolio that rivals major nations, as demand for its USDT token continues to surge globally.
Extreme Networks reports Q2 revenue of $317.9M and net income of $7.9M, while launching an AI-integrated partner initiative aimed at streamlining sales and driving higher-margin software revenue.
Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.
Amid escalating tensions and a U.S. military buildup in the Gulf, Iran's foreign minister has declared the country's missile capabilities 'non-negotiable,' setting the stage for a precarious diplomatic standoff.
The drive-thru coffee chain 7 Brew debuts a monthly rotating menu of featured beverages, starting with five options for February including a new Chocolate Dipped Strawberry Cold Brew, as it leverages its strong rewards membership to boost visit frequency.
Erasca Inc. (ERAS) sees its price target raised from $5 to $12 by Guggenheim, following promising clinical data for its lead oncology candidates and updated financial models. The move comes amid a series of positive analyst revisions for the clinical-stage biopharma firm.
Iran's foreign minister has unequivocally declared the nation's missile and defense capabilities non-negotiable, even as diplomatic efforts intensify to prevent a military escalation with the United States. The statement comes amid a complex backdrop of regional mediation and internal unrest.
Iran's foreign minister stated readiness for 'fair' negotiations with Washington but firmly ruled out discussing its defense capabilities, as regional powers intensify diplomacy to avert a military confrontation.
The Singapore-listed port operator has significantly improved its capital efficiency over five years, rewarding shareholders. Analysts are now weighing whether this trend is sustainable for long-term growth.
